Igene Biotechnology, Inc.
IGNE
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 4.80K | 1.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 4.80K | 1.12M |
| Cost of Revenue | -- | -- | -- | -36.00K | 461.50K |
| Gross Profit | -- | -- | -- | 40.80K | 654.30K |
| SG&A Expenses | 141.50K | 295.60K | 208.90K | 297.60K | 259.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -573.70K | -682.10K | -531.00K | -559.90K | -619.40K |
| Total Operating Expenses | 95.40K | 126.60K | 147.60K | 231.90K | 544.20K |
| Operating Income | -95.40K | -126.60K | -147.60K | -227.10K | 571.60K |
| Income Before Tax | -627.20K | -811.20K | -549.00K | -386.40K | 114.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -627.20K | -811.20K | -549.00K | -386.40K | 114.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -627.20K | -811.20K | -549.00K | -386.40K | 114.80K |
| EBIT | -95.40K | -126.60K | -147.60K | -227.10K | 571.60K |
| EBITDA | -50.10K | -81.30K | -102.20K | -193.50K | 620.40K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.57B | 1.57B | 1.56B | 1.56B | 1.55B |
| Average Diluted Shares Outstanding | 1.57B | 1.57B | 1.56B | 1.56B | 1.55B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |